Advertisement

L’Endocrinologo

, Volume 3, Issue 2, pp 166–175 | Cite as

Terapia della malattia di Cushing

  • Francesca Pecori Giraldi
  • Francesco Cavagnini
Article
  • 21 Downloads

Riassunto

La malattia di Cushing è una patologia che a tutt’oggi non dispone di un trattamento pienamente soddisfacente. Il primo approccio terapeutico, la rimozione dell’adenoma ipofisario secernente ACTH, si rivela risolutivo, infatti, nel 70% circa dei pazienti con un rischio di recidiva del 15%. Delle restanti opzioni terapeutiche, reintervento ipofisario, terapia radiante e surrenectomia bilaterale, solo quest’ultima dà garanzie di guarigione a spese, però, della necessità di una terapia sostitutiva ad vitam. La terapia farmacologica ha solamente una valenza di ripiego nei pazienti inoperabili o in attesa di efficacia della terapia radiante. Pur con queste limitazioni, è tuttavia possibile, attraverso un uso oculato delle diverse risorse terapeutiche, talvolta impiegate in successione e/o in concomitanza, portare alla guarigione la maggior parte dei pazienti.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. 1.
    Invitti C, Pecori Giraldi F, De Martin M, Cavagnini F, the Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. J Clin Endocrinol Metab 84: 440, 1999.PubMedGoogle Scholar
  2. 2.
    Lüdecke DK, Flitsch J, Knappe UJ, Saeger W. Cushing’s disease: a surgical view. J Neurooncol 54: 151, 2001.PubMedCrossRefGoogle Scholar
  3. 3.
    Chee GH, Mathias DB, James RA, Kendall-Taylor P. Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clin Endocrinol 54: 617, 2001.CrossRefGoogle Scholar
  4. 4.
    Bochicchio D, Losa M, Buchfelder M, the European Cushing’s Disease Survey Group. Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. J Clin Endocrinol Metab 80: 3114, 1995.PubMedGoogle Scholar
  5. 5.
    Semple PL, Laws ER Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing’s disease. J Neurosurg 91: 175, 1999.PubMedCrossRefGoogle Scholar
  6. 6.
    Nagesser SK, van Seters AP, Kievit J, Hermans J, Kraus JMJ, van de Velde CJH. Long-term results of total adrenalectomy for Cushing’s disease. World J Surg 24: 108, 2000.PubMedCrossRefGoogle Scholar
  7. 7.
    Grabner P, Hauer-Jensen M, Jervell J, Flatmark A. Long-term results of treatment of Cushing’s disease by adrenalectomy. Eur J Surg 157: 461, 1991.PubMedGoogle Scholar
  8. 8.
    Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 336: 172, 1997.PubMedCrossRefGoogle Scholar
  9. 9.
    Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler GB Jr, Nieman LK, Chrousos GP. Cushing’s syndrome in children and adolescents. N Engl J Med 331: 629, 1994.PubMedCrossRefGoogle Scholar
  10. 10.
    Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317: 812, 1987.PubMedCrossRefGoogle Scholar
  11. 11.
    Kawai S, Ichikawa Y, Kaburaki J, Yoshida T. 18 years mitotane therapy for intractable Cushing’s disease. Lancet 354: 951, 1999.PubMedGoogle Scholar
  12. 12.
    Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JAH, Besser GM. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol 35: 169, 1991.CrossRefGoogle Scholar
  13. 13.
    Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of reafractory Cushing’s disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86: 3568, 2001.PubMedGoogle Scholar
  14. 14.
    Mercado-Asis LB, Yasuda K, Murayama M, Mune T, Morita H, Kiura K. Beneficial effects of high daily dose bromocriptine treatment in Cushing’s disease. Endocrinol Japan 39: 385, 1992.CrossRefGoogle Scholar
  15. 15.
    Koppeschaar HPF, Croughs RJM, Thijssen JHH, Schwarz F. Response to neurotransmitter modulating drugs in patients with Cushing’s disease. Clin Endocrinol 25: 661, 1986.CrossRefGoogle Scholar
  16. 16.
    Krieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing’s disease. N Engl J Med 293: 893, 1975.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2002

Authors and Affiliations

  • Francesca Pecori Giraldi
    • 1
  • Francesco Cavagnini
    • 1
  1. 1.Divisione di Endocrinologia, Ospedale San Luca IRCCS, Istituto Auxologico ItalianoUniversità di MilanoMilanoItalia

Personalised recommendations